Log in to save to my catalogue

Development and validation of the post-CAR prognostic index for large B-cell lymphoma patients after...

Development and validation of the post-CAR prognostic index for large B-cell lymphoma patients after...

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_7a33c510abd6496482324ad69e68ca9f

Development and validation of the post-CAR prognostic index for large B-cell lymphoma patients after CAR-T progression in third or later line treatment

About this item

Full title

Development and validation of the post-CAR prognostic index for large B-cell lymphoma patients after CAR-T progression in third or later line treatment

Publisher

England: BioMed Central Ltd

Journal title

Journal of hematology and oncology, 2024-10, Vol.17 (1), p.102-10, Article 102

Language

English

Formats

Publication information

Publisher

England: BioMed Central Ltd

More information

Scope and Contents

Contents

Chimeric antigen receptor (CAR) T-cell therapy fails to achieve durable responses in over 60% of relapsed/refractory (R/R) large B-cell lymphoma (LBCL) patients in the third or later line setting. After CAR-T failure, survival outcomes are heterogeneous and a prognostic model in this patient population is lacking. A training cohort of 216 patients...

Alternative Titles

Full title

Development and validation of the post-CAR prognostic index for large B-cell lymphoma patients after CAR-T progression in third or later line treatment

Identifiers

Primary Identifiers

Record Identifier

TN_cdi_doaj_primary_oai_doaj_org_article_7a33c510abd6496482324ad69e68ca9f

Permalink

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_7a33c510abd6496482324ad69e68ca9f

Other Identifiers

ISSN

1756-8722

E-ISSN

1756-8722

DOI

10.1186/s13045-024-01608-8

How to access this item